Spectrum of cardiac abnormalities associated with long QT in stroke survivors.

Item

http://www.wikidata.org/entity/Q35584793

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Spectrum of cardiac abnormalities associated with long QT in stroke survivors.

@ast

Spectrum of cardiac abnormalities associated with long QT in stroke survivors.

@en

type

Item

label

Spectrum of cardiac abnormalities associated with long QT in stroke survivors.

@ast

Spectrum of cardiac abnormalities associated with long QT in stroke survivors.

@en

prefLabel

Spectrum of cardiac abnormalities associated with long QT in stroke survivors.

@ast

Spectrum of cardiac abnormalities associated with long QT in stroke survivors.

@en

P1476

Spectrum of cardiac abnormalities associated with long QT in stroke survivors.

@en

P2093

A D Struthers

http://www.w3.org/2001/XMLSchema#string

A Gavin

http://www.w3.org/2001/XMLSchema#string

K Y K Wong

http://www.w3.org/2001/XMLSchema#string

N S J Kennedy

http://www.w3.org/2001/XMLSchema#string

R S MacWalter

http://www.w3.org/2001/XMLSchema#string

S McSwiggan

http://www.w3.org/2001/XMLSchema#string

S Y S Wong

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology

Measurement of heart rate variability: a clinical tool or a research toy?

Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Should we add screening for and treating left ventricular hypertrophy to the management of all patients needing secondary prevention of cardiovascular disease?

Long QTc predicts future cardiac death in stroke survivors

Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.

Hypothetical economic analysis of screening for left ventricular hypertrophy in high-risk normotensive populations.

P304

1306-1310

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/HRT.2004.045187

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7599642

http://www.w3.org/2001/XMLSchema#string

P698

16162622

http://www.w3.org/2001/XMLSchema#string

P932

1769139

http://www.w3.org/2001/XMLSchema#string